Enliven Therapeutics, Inc. · NASDAQ:ELVN

Orbimed Advisors LLC reported a 13.40% stake in Enliven Therapeutics, Inc. (Schedule 13D/A)

Event Jun 16, 2025 · Filed Jun 17, 2025

Orbimed Advisors LLC reported a 13.40% stake in Enliven Therapeutics, Inc., 7,918,163 shares, with active intent on Jun 16, 2025. Filed Jun 17, 2025 (Schedule 13D/A).

Stake
13.40%
Shares
7,918,163
Intent
Active
What changed
Stake changed
Filed together
4 holders

The filing in full

HolderStakeShares
ORBIMED ADVISORS LLC13.40%7,918,163
ORBIMED CAPITAL GP VII LLC13.00%7,663,349
ORBIMED GENESIS GP LLC0.40%254,814
ORBIMED CAPITAL LLC0.10%41,375

Source

View original at SEC

Related